Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

• 1. Voluntarily agree to join this clinical trial, sign the informed consent form, and follow all trial arrangements, including scheduled hospital visits, examinations and other study requirements. 2. Age between 18 and 80 years old (including 18 and 80 years old) at the time of signing the informed consent form. 3. Diagnosed with non-squamous non-small cell lung cancer (NSCLC) confirmed by pathological or cytological tests. The disease must be either locally advanced and unresectable (not suitable for radical chemoradiotherapy) or metastatic advanced lung cancer. 4. Must have a clear EGFR gene test result before enrollment. Patients with other actionable gene mutations (excluding EGFR mutation) are eligible. Testing for other genes is not mandatory, and can be performed according to local hospital routine standards and available treatment options. 5. Have received no more than one line of chemotherapy for advanced or metastatic lung cancer. Neoadjuvant or adjuvant chemotherapy will be counted as one prior chemotherapy line if the disease progresses within 6 months after the end of treatment. 6. Have received at least one prior formal treatment (chemotherapy, targeted therapy or immunotherapy) for advanced or metastatic lung cancer, with subsequent disease progression or recurrence. Participants must meet the corresponding requirements based on their genetic status: 6.1 Patients without any actionable gene mutations: Have experienced disease progression after platinum-based chemotherapy and immune checkpoint inhibitor therapy (used alone or combined with chemotherapy), or are not suitable for the above two treatments clinically. 6.2 Patients with gene mutations that do not routinely use immunotherapy (e.g., ALK fusion): Have experienced disease progression after targeted therapy for gene mutations and platinum-based chemotherapy, or are not suitable for the above two treatments clinically. 6.3 Patients with gene mutations for which immunotherapy is a conventional treatment: Have also experienced disease progression after immune checkpoint inhibitor therapy (used alone or combined with chemotherapy), or are not suitable for immunotherapy clinically. 7. The investigator confirms that the patient is suitable for docetaxel treatment (only applicable for Phase 3 trial). 8. Have at least one measurable tumor lesion assessed by RECIST 1.1 criteria. 9. ECOG physical status score is 0 or 1, with normal daily physical activity. 10. Expected survival time is at least 12 weeks. 11. Have normal and stable organ function. No blood transfusion, erythropoietin, thrombopoietin, granulocyte colony-stimulating factor or other supportive treatment within 14 days before the test, and meet the following laboratory standards:
• Blood routine: Absolute neutrophil count ≥ 1.5 × 10/L; platelet count ≥ 100 × 10/L; hemoglobin ≥ 90 g/L
• Renal function: Creatinine clearance ≥ 50 mL/min (calculated by Cockcroft-Gault formula)
• Liver function: Total bilirubin ≤ 1.5 times the upper limit of normal (or ≤ 3 times the upper limit of normal for patients with Gilbert's disease); AST and ALT ≤ 2.5 times the upper limit of normal (or ≤ 5 times the upper limit of normal for patients with liver metastases)
• Coagulation function: INR or aPTT ≤ 1.5 times the upper limit of normal for patients not receiving anticoagulant treatment 12. Female patients of childbearing age must use two effective contraceptive methods during the trial treatment period and within 12 weeks after the last dose of trial drug. A negative serum pregnancy test is required within 7 days before enrollment. Postmenopausal women (no menstruation for 12 consecutive months) or surgically sterilized women are exempted. 13. Male patients must use latex condoms during treatment and within 12 weeks after the last dose of trial drug (even after vasectomy). All patients are prohibited from donating sperm (male) or eggs (female) during the trial and within 12 weeks after the last drug dose.

I. General